PASI A contact JANNE

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program
    Pasi A Janne
    Lowe Center for Thoracic Oncolgy, Dana Farber Cancer Institute, Boston, MA, USA
    Clin Lung Cancer 7:40-6. 2005
  2. doi request reprint Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial
    Pasi A Janne
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, MA, USA Belfer Institute for Applied Cancer Science, Dana Farber Cancer Institute, Boston, MA, USA Electronic address
    Lancet Oncol 15:1433-41. 2014
  3. pmc New targetable oncogenes in non-small-cell lung cancer
    Geoffrey R Oxnard
    Dana Farber Cancer Institute, Brigham and Women s Hospital, and Harvard Medical School, Boston, MA 02215, USA
    J Clin Oncol 31:1097-104. 2013
  4. ncbi request reprint Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program
    Pasi A Janne
    Department of Medical Oncology, Dana Farber Cancer Institute and Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    J Thorac Oncol 1:506-12. 2006
  5. doi request reprint Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours
    Pasi A Janne
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Lung Cancer 60:S3-9. 2008

Detail Information

Publications5

  1. ncbi request reprint Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program
    Pasi A Janne
    Lowe Center for Thoracic Oncolgy, Dana Farber Cancer Institute, Boston, MA, USA
    Clin Lung Cancer 7:40-6. 2005
    ..Before the regulatory approval of pemetrexed, an expanded access program (EAP) provided access to eligible patients with malignant pleural or peritoneal mesothelioma...
  2. doi request reprint Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial
    Pasi A Janne
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, MA, USA Belfer Institute for Applied Cancer Science, Dana Farber Cancer Institute, Boston, MA, USA Electronic address
    Lancet Oncol 15:1433-41. 2014
    ..We did a trial of dacomitinib as initial systemic therapy in clinically and molecularly selected patients with advanced non-small-cell lung cancer...
  3. pmc New targetable oncogenes in non-small-cell lung cancer
    Geoffrey R Oxnard
    Dana Farber Cancer Institute, Brigham and Women s Hospital, and Harvard Medical School, Boston, MA 02215, USA
    J Clin Oncol 31:1097-104. 2013
    ....
  4. ncbi request reprint Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program
    Pasi A Janne
    Department of Medical Oncology, Dana Farber Cancer Institute and Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    J Thorac Oncol 1:506-12. 2006
    ..To gather additional efficacy and safety data of pemetrexed/cisplatin and pemetrexed alone in previously treated patients, we examined patients treated on the Eli Lilly and Company expanded access program (EAP)...
  5. doi request reprint Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours
    Pasi A Janne
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Lung Cancer 60:S3-9. 2008
    ..In this way, treatment strategies in NSCLC are becoming increasingly tailored to the individual, and may set an example for other areas of oncology...